November 19, 2025. Leads & Copy —
Synthio Labs, a voice AI company focused on the life sciences sector, has secured $5 million in seed funding. The round was spearheaded by Elevation Capital, with participation from 1984 Ventures, Peak XV Partners, Y Combinator, and other angel investors from the healthcare and AI industries.
The funding will be used to expand Synthio Labs’ engineering and product teams, scale enterprise deployments in the U.S. and Europe, and strengthen partnerships with life science clients.
Krishna Mehra, AI Partner at Elevation Capital, said Synthio Labs is defining the next major customer engagement infrastructure for life sciences. Mehra also stated that their clinical-grade voice AI platform unifies how pharma communicates, giving field teams a powerful voice companion and providing physicians and patients with instant, trusted, compliant answers 24/7. He also noted that pharma’s global commercial and GTM footprint is a trillion-dollar machine ripe for reinvention, and Synthio has exactly the right team to deliver on this mission.
Synthio Labs is addressing the challenge of fragmented and manual communication in the pharmaceutical industry, where companies spend over $30 billion annually on doctor and patient engagement. The company’s Voice AI technology is designed to deliver clear, accurate medical information to doctors and patients, reducing treatment drop-off rates, which can reach up to 50% in long-term illnesses.
The company’s AI Operating System unifies three flagship platforms: Jarvis, Ather, and Simulation Studio. Jarvis is a clinical-grade Voice AI copilot for field teams. Ather is a multimodal AI engine that powers omnichannel engagement with physicians and patients. Simulation Studio is an insight platform that generates digital twins of clinicians and patients for research and strategy. The platforms help life-sciences teams automate compliant conversations, capture structured intelligence at scale, and deliver human-grade experiences.
Supreet Deshpande, Co-founder and CEO of Synthio Labs, said that beyond breakthrough medicines, the future of healthcare will depend on how we reach and support every clinician and patient who relies on them.
Sahitya Sridhar, Co-founder and Chief Product Officer, stated that Synthio Labs is designing products that make every conversation between pharma and their customers smarter, faster, and more meaningful.
Rafal Pielak, Founder and CEO, Soteri Skin, said, Synthio Labs built a voice AI agent that engaged thousands of eczema patients, completing 5,000 calls in just two days. The agent supported onboarding, screening, and patient assistance end-to-end, fully automating our feedback and review collection. We’re very happy with the results and look forward to working together again.
Synthio Labs was founded by Supreet Deshpande, Sahitya Sridhar and Rajashekar Vasantha. The company is headquartered in the San Francisco Bay Area with teams across India and the U.S.
Contact:
Synthio Labs
Source: Synthio Labs
